Chemopreventive and Bioenergetic Signaling Effects of PDK1/Akt Pathway Inhibition in a Transgenic Mouse Model of Prostate Cancer

Toxicologic Pathology

Volumn 35, Issue 4, 2007, Pages 549-561

  Sargeant, Aaron M ^a   Klein, Russell D ^a   Rengel, Robert C ^a   Clinton, Steven K ^b   Kulp, Samuel K ^a   Kashida, Yoko ^a   Yamaguchi, Mamoru ^a   Wang, Xingya ^a   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Akt; chemoprevention; myonecrosis; OSU03012; PDK1; prostate; TRAMP

Indexed keywords

GLYCOGEN SYNTHASE; OSU 03012; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; BIOENERGY; BODY FAT; CANCER INCIDENCE; CANCER SIZE; CARCINOMA; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIUM CELL; FOOD INTAKE; HYPERTROPHY; MALE; METASTASIS; MOUSE; MUSCLE FIBRIL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE; WEIGHT GAIN;

ADENOCARCINOMA; ADIPOSE TISSUE; ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; EATING; ENZYME INHIBITORS; EPITHELIUM; GLYCOGEN SYNTHASE KINASE 3; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MUSCLE FIBERS, FAST-TWITCH; NECROSIS; ORGAN SIZE; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

MUS; MUS MUSCULUS;

EID: 34250355904     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230701338966     Document Type: Article

References (54)

1. Abate-Shen C Shen MM Mouse models of prostate carcinogenesis Trends Genet 2002 18 5 S1 5
2. Bodine SC Stitt TN Gonzalez M Kline WO Stover GL Bauerlein R Zlotchenko E Scrimgeour A Lawrence JC Glass DJ Yancopoulos GD Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent atrophy in vivo Nat Cell Biol 2001 3 1014 19
3. Bolon B Genetically engineered animals in drug discovery and development: a maturing resource for toxicologic research Basic Clin Pharmacol Toxicol 2004 95 4 154 61
4. Bregman CL Adler RR Morton DG Regan KS Yano BL Recommended tissue list for histopathologic examination in repeat-dose toxicity and carcinogenicity studies: a proposal of the Society of Toxicologic Pathology (STP) Toxicol Pathol 2003 31 2 252 3
5. Cross DA Alessi DR Cohen P Andjelkovich M Hemmings BA Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B Nature 1995 378 6559 785 9
6. Draeger A Monastyrskaya K Mohaupt M Hoppeler H Savolainen H Allemann C Babiychuk EB Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia J Pathol 2006 210 1 94 102
7. Edwards J Krishna NS Witton CJ Bartlett JM Gene amplifications associated with the development of hormone-resistant prostate cancer Clin Cancer Res 2003 9 14 5271 81
8. Elstrom RL Bauer DE Buzzai M Karnauskas R Harris MH Plas DR Zhuang H Cinalli RM Alavi A Rudin CM Thompson CB Akt stimulates aerobic glycolysis in cancer cells Cancer Res 2004 64 11 3892 9
9. Food and Drug Administration Celebrex label 2005 〈http://www.fda.gov/cder/foi/label/2005/020998s018,019lbl.pdf〉.
10. Ghadially FN Endoplasmic reticulum Ultrastructural Pathology of the Cell and Matrix 1982 2 Great Britain William Clowes (Beccles) Limited, Beccles and London 370 838
11. Greaves P Digestive System 2 Histopathology of Preclinical Toxicity Studies. Interpretation and Relevance in Drug Safety Evaluation 2000 2 Elsevier 435 52
12. Greenberg NM DeMayo F Finegold MJ Medina D Tilley WD Aspinall JO Cunha GR Donjacour AA Matusik RJ Rosen JM Prostate cancer in a transgenic mouse Proc Natl Acad Sci U S A 1995 92 8 3439 43
13. Gupta S Prostate cancer chemoprevention: models, limitations and potential (Review) Int J Oncol 2004 25 4 1133 48
14. Gupta S Hastak K Ahmad N Lewin JS Mukhtar H Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols Proc Natl Acad Sci USA 2001 98 18 10350 5
15. Hsu AL Ching TT Wang DS Song X Rangnekar VM Chen CS The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2 J Biol Chem 2000 275 15 11397 403
16. Ihle NT Paine-Murrieta G Berggren MI Baker A Tate WR Wipf P Abraham RT Kirkpatrick DL Powis G The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts Mol Cancer Ther 2005 4 9 1349 57
17. Johnson AJ Smith LL Zhu J Heerema NA Jefferson S Mone A Grever M Chen CS Byrd JC A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism Blood 2005 105 6 2504 9
18. Klein RD The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research Mutation Res 2005 576 111 19
19. Knight ZA Gonzalez B Feldman ME Zunder ER Goldenberg DD Williams O Loewith R Stokoe D Balla A Toth B Balla T Weiss WA Williams RL Shokat KM A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling Cell 2006 125 4 733 47
20. Komander D Kular GS Bain J Elliott M Alessi DR Van Aalten DM Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition Biochem J 2003 375 Pt 2 255 62
21. Kondapaka SB Zarnowski M Yver DR Sausville EA Cushman SW 7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport Clin Cancer Res 2004 10 21 7192 8
22. Kucab JE Lee C Chen CS Zhu J Gilks CB Cheang M Huntsman D Yorida E Emerman J Pollak M Dunn SE Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours Breast Cancer Res 2005 7 5 R796 807
23. Kulp SK Yang YT Hung CC Chen KF Lai JP Tseng PH Fowble JW Ward PJ Chen CS 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells Cancer Res 2004 64 4 1444 51
24. Lawlor MA Mora A Ashby PR Williams MR Murray-Tait V Malone L Prescott AR Lucocq JM Alessi DR Essential role of PDK1 in regulating cell size and development in mice Embo J 2002 21 14 3728 38
25. Leininger JR Maronpot RR Boorman GA Gaul BW Skeletal muscle Pathology of the Mouse 1999 1 Vienna, IL Cache River Press 637
26. Li L Ittmann MM Ayala G Tsai MJ Amato RJ Wheeler TM Miles BJ Kadmon D Thompson TC The emerging role of the PI3-K-Akt pathway in prostate cancer progression Prostate Cancer Prostatic Dis 2005 8 2 108 18
27. Liao Y Grobholz R Abel U Trojan L Michel MS Angel P Mayer D Increase of AKT/PKB expression correlates with Gleason pattern in human prostate cancer Int J Cancer 2003 107 4 676 80
28. McCabe MT Low JA Daignault S Imperiale MJ Wojno KJ Day ML Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer Cancer Res 2006 66 1 385 92
29. McCubrey JA LaHair MM Franklin RA OSU-03012 in the treatment of glioblastoma Mol Pharmacol 2006 70 2 437 39
30. McDonald MM Hamilton BF Boorman GA Eustis SL Elwell MR Montgomery CA MacKenzie WF Skeletal muscle Pathology of the Fischer Rat 1990 San Diego, CA Academic Press, Inc 202
31. Mimeault M Batra SK Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies Carcinogenesis 2006 27 1 1 22
32. Mora A Sakamoto K McManus EJ Alessi DR Role of the PDK1-PKB-GSK3 pathway in regulating glycogen synthase and glucose uptake in the heart FEBS Lett 2005 579 17 3632 8
33. Narayanan BA Narayanan NK Pittman B Reddy BS Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model Clin Cancer Res 2004 10 22 7727 37
34. Nielsen JN Derave W Kristiansen S Ralston E Ploug T Richter EA Glycogen synthase localization and activity in rat skeletal muscle is strongly dependent on glycogen content J Physiol 2001 531 757 69
35. Orho M Bosshard NU Buist NR Gitzelmann R Aynsley-Green A Blumel P Gannon MC Nuttall FQ Groop LC Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0 J Clin Invest 1998 102 3 507 15
36. Pederson BA Schroeder JM Parker GE Smith MW Depaoli-Roach AA Roach PJ Glucose metabolism in mice lacking muscle glycogen synthase Diabetes 2005 54 12 3466 73
37. Plas DR Thompson CB Akt-dependent transformation: there is more to growth than just surviving Oncogene 2005 24 50 7435 42
38. Plyte SE Hughes K Nikolakaki E Pulverer BJ Woodgett JR Glycogen synthase kinase-3: functions in oncogenesis and development Biochem Biophys Acta 1992 1114 2–3 147 62
39. Raghow S Hooshdaran MZ Katiyar S Steiner MS Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model Cancer Res 2002 62 5 1370 6
40. Raghow S Kuliyev E Steakley M Greenberg N Steiner MS Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model Cancer Res 2000 60 15 4093 7
41. Rommel C Bodine SC Clarke BA Rossman R Nunez L Stitt TN Yancopoulos GD Glass DJ Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways Nat Cell Biol 2001 3 11 1009 13
42. Suckow MA Danneman P Brayton C Suckow MA Important biological features The Laboratory Mouse 2001 Boca Raton, Florida CRC Press 12
43. Suttie AW Dinse GE Nyska A Moser GJ Goldsworthy TL Maronpot RR An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse Toxicol Pathol 2005 33 3 386 97
44. Suttie A Nyska A Haseman JK Moser GJ Hackett TR Goldsworthy TL A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model Toxicol Pathol 2003 31 1 31 8
45. Thompson CB Metabolic regulation of cancer cell survival. In Mechanisms of toxicity, carcinogenesis, cancer prevention and cancer therapy. The Twentieth Aspen Cancer Conference. Session 8. Apoptosis Toxicol Pathol 2005 33 7 829 31
46. Tomita Y Morooka T Hoshida Y Zhang B Qiu Y Nakamichi I Hamada K Ueda T Naka N Kudawara I Aozasa K Prognostic significance of activated AKT expression in soft-tissue sarcoma Clin Cancer Res 2006 12 3070 7
47. Tseng PH Lin HP Zhu J Chen KF Hade EM Young DC Byrd JC Grever M Johnson K Druker BJ Chen CS Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance Blood 2005 105 4021 7
48. Tseng PH Weng SC Wang YC Weng JR Chen CS Brueggemeier RW Shapiro CL Chen CY Dunn SE Pollak M Chen CS Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived PDK-1 inhibitor Mol Pharmacol 2006 Epub ahead of print
49. Watanabe T Manabe S Ohashi Y Okamiya H Onodera H Mitsumori K Comparison of the induction profile of hepatic drug-metabolizing enzymes between piperonyl butoxide and phenobarbital in rats J Toxicol Pathol 1998 11 1 10
50. Wechter WJ Leipold DD Murray ED Jr Quiggle D McCracken JD Barrios RS Greenberg NM E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse Cancer Res 2000 60 8 2203 8
51. Westwood FR Bigley A Randall K Marsden AM Scott RC Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity Toxicol Pathol 2005 33 2 246 57
52. Xie Z Yuan H Yin Y Zeng X Bai R Glazer RI 3-phosphoinositide-dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases BMC Cancer 2006 6 77
53. Yang L Dan HC Sun M Liu Q Sun XM Feldman RI Hamilton AD Polokoff M Nicosia SV Herlyn M Sebti SM Cheng JQ Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt Cancer Res 2004 64 13 4394 9
54. Zhu J Huang JW Tseng PH Yang YT Fowble J Shiau CW Shaw YJ Kulp SK Chen CS From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors Cancer Res 2004 64 12 4309 18